Janssen gets EC approval for Darzalex combination regimen to treat multiple myeloma

This article was originally published here

Daratumumab is a first-in-class biologic designed to target CD38, a surface protein that is highly expressed across multiple myeloma cells, regardless of disease stage. Daratumumab is considered to

The post Janssen gets EC approval for Darzalex combination regimen to treat multiple myeloma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply